On 1 June 2011, the US Federal Trade Commission (FTC) announced that it had challenged the acquisition of Talecris Biotherapeutics Holdings Corp. (Talecris) by Grifols, S.A. (Grifols), alleging that the acquisition would substantially lessen competition in plasma-derived product markets in the United States in violation of Section 7 of the Clayton Act and Section 5 of the FTC Act. The FTC has accepted a consent agreement proposed by Grifols and Talecris to settle the FTC's challenge under which the parties have agreed to divest certain Talecris assets to Kedrion S.p.A., a manufacturer of plasma-derived products in Europe and other markets.